IMS Health Holdings (IMS) : Zacks Investment Research ranks IMS Health Holdings (IMS) as 3, which is a Hold recommendation. 5 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. A total of 4 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 9 research analysts is 1.89, which indicates as a Buy.
IMS Health Holdings (IMS) : 8 investment research analysts covering IMS Health Holdings (IMS) have an average price target of $32.13 for the near short term. The highest target price given by the Brokerage Firm to the stock is $38 and the lowest target is $26 for the short term. Analysts expect the variance to be within $3.64 of the average price.
IMS Health Holdings (NYSE:IMS): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $26.17 and $25.99 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $26.36. The buying momentum continued till the end and the stock did not give up its gains. It closed at $26.29, notching a gain of 0.31% for the day. The total traded volume was 1,368,910 . The stock had closed at $26.21 on the previous day.
Also, Wells Fargo downgrades its rating on IMS Health Holdings (NYSE:IMS). Analysts at the Wells Fargo have a current rating of Market Perform on the shares. The shares were previously rated Outperform. The rating by the firm was issued on May 12, 2016. The company shares have dropped -12.75% from its 1 Year high price. On Jul 31, 2015, the shares registered one year high at $33.52 and the one year low was seen on Jan 28, 2016. The 50-Day Moving Average price is $25.31 and the 200 Day Moving Average price is recorded at $25.28.
IMS Health Holdings, Inc. (IMS) is an information and technology services company that provides solutions to its clients in the healthcare industry. The Company has its presence in over 100 countries. The Companys data set contains over 10 petabytes of data and over 500 million patient records. The Company serves healthcare organizations and life science companies, including pharmaceutical, biotechnology, consumer health and medical device manufacturers, as well as distributors, providers, payers, government agencies, policymakers, researchers and the financial community. The Companys principal offerings include national information offerings, sub-national information offerings, workflow analytics, real-world evidence (RWE) solutions, technology and applications and clinical solutions.